Member Info for dallo

Mark

Markets don't like Gallops LYT-200 results and the Luba Greenwood situation.

Again poor management by Puretech

The Puretech Paradox I am afraid.

No good news will budge the SP upwards.

This has to change imo as more important newsflow is released.

I have contacted Puretech's Investor Relations asking why Eric Elenko is now Acting CEO and was has happened to Luba Greenwood, the Co Founder and CEO of Gallop .

If she has left the company then this is Market Relevant Information and must be disclosed.

This may explain the strangely muted Market response to the good news from Gallop.

1st of my short term mega catalysts now out.

Incredible top line data from Gallop and moving LYT-200 to pre registration with FDA .

Gallop Oncology could be the biggest of all Puretech's irons in the fire.

Great news

JSB

Good to see you back in Puretech.

Major inflection points coming in the next few months namely Puretech's 2025 Annual Results next week, BMS 1st quarter results and Cobenfy revenues on the 30th April , Celea financing, Gallop Oncology updates on continuing trial results and financing plus Seaport's IPO rumoured for the 1st weeks in May.

Finally some short term mega catalysts to drive the rerate of the the moribund share price.

Fingers crossed

ATB

Expect Saba and Actus with their combined c 2.6m shares in short positions to be scrambling for the exits soon which should add further buying momentum.

The US market may also see some action today as you can get pre IPO exposure to Seaport by simply buying Puretech with its 36% shareholding and sizeable Royalties in Seaport.

I expect further upward movement in the SP in the short-term.

Tuscany

If Seaport is confident enough to finance it's Phase 2 depression/anxiety drugs via the stock market then it begs the question as to why Celea doesn't do the same with it's advanced LYT-100 IPF drug now fast tracked into Phase 3 trial with a supportive FDA behind it.

Celea could get a $1 billion plus valuation if listed.

If it were to happen then Puretech could soar by a factor of 5 to 10 times when you add in the other assets on its Balance Sheet.

Just a thought for the day!

Rock

Agree but we will get an exact figure when the 2025

Results are announced in a couple of weeks.

Still doesn't change the bizarre undervaluation of Puretech in the Stock Markets.

ATB

If Seaport is going for an IPO for its Phase 2 depression therapy drug at a possible valuation in excess of $1billion then what valuation would you assign to Celea with its Phase 3 IPF LYT-100 potential blockbuster and Gallop Oncology's hard cancer tumours LYT-200 drugs .

Mind boggling and throw in cash of c $300m plus

Cobenfy royalties of c$400 m all for a current Puretech market cap of £275m.

Bonkers

Golfnut

Excellent analysis.

Crazy valuation of Puretech should now be rectified by the Market on Monday.

Share price on Nasdaq jumped in after hours trade to $17.50 or £1.30 sterling equivalent.

I expect shorts to rush to close on Monday and share price to reflect this great news from Seaport.

ATB

Golfnut

Huge news indeed.

Seaport could list with a market cap in excess of $1 billion.

The key question now is will Puretech take up some of the new subscription shares to avoid dilution.

I expect the market to react very positively to this news and if accompanied by news on Celea , could rocket the share price.

Great stuff at last

Snowking

Excellent updates from Seaport and Celea last week has been met with the usual utter disdain from the market with the SP still rooted at near all time lows.

Even Actusraypartners has increased its short position to add insult to injury.

I don't have a clue anymore about Puretech as it operates in a parallel world far from our reality.

And again Oak Bloke forgot to add Gallop Oncology to to the list of Puretech's assets in his otherwise fine analysis.

Gallop could be the biggest of them all albeit at an early stage of its development.

Seaport's announcement of the latest scientific findings of its Glyph Allo drug as an oral therapy for depression is another milestone in its development to full commercialisation and could be as big as Cobenfy was for Karuna.

Dyphne Zohar and the team from Puretech who developed Cobenfy are now focusing on Glyph Allo as a mega blockbuster treatment for major depression.

If it comes to the market I will be the first to take it after being an investor in Puretech for 8 years and during which time my mental health has deteriorated dramatically!

And to compound the bizarre nature of this share, Actusray partners has just taken out a short position last for .51% of the total shares in issue to add to Saba's existing short of .51%.

I am bamboozled and at a loss to see why the market utterly detests this share.

It looks like Lyne is another absolute waster and still no announcement of a permanent Chairman being appointed.

Desperate stuff.

When Lyne was appointed last July the SP was 147p.

It is now 119p and newsflow of any importance has dried up apart from futile attendances at conferences.

The SP is totally stuck at near alltime lows and investor interest practically non existent with tiny volumes of shares traded each day .

Nothing from brokers or media .Puretech might as well not be listed on the Stock Exchange.

A Zombie company just trudging along with abject Board and Management.

Sad waste of time for loyal investors here.

Frank

I don't blame you for selling up but I am awaiting the Celea financing and the 2025 Annual Results announcement in April which will be a hallmark moment for Lyne and his management team .

Lyne has to reassure the market very soon as to Puretech's strategy on enhancing Shareholder value .

If no progress by May I will be selling my c200,000 shares as sadly , given my advanced years, I cannot endure another year of jam tomorrow.

ATB

Snowking

The analysis by the Oak Bloke is severely compromised by his failure to mention Gallop Oncology which could be a mega winner.

Sloppy but shows the huge disconnect between valuation and stock market pricing.

He could have really enhanced his thesis by highlighting Gallop.

Shareholders be damned!

The share price is now close to all time lows despite the reduction in number of shares in issue to just c240 million.

Lyne is just another in a long line of inept management clinging on to the failed corporate strategy of this bizarre hub and spoke model despised by the market and investors .

Everyone who has invested in Puretech has lost money but management continues to pay itself top salaries for abject failure.

I advised the company's management via Investor Relations to focus solely on enhancing Shareholder value at any cost and was advised by Lyne that this was their primary objective.

That was 9 months ago and nothing since then.

I am not convinced the funding of Celea will change matters .

Anyway decision time for me personally as 8 years of stasis is too long at my advanced age!

ATB

RNS clarifies the current state of play regarding LYT-100 and the significant FDA approval of Orphan Drug Status adds to the positivity of the update.

I have said exactly the same thing in a previous post here.

The average cost of a 52 week Phase 3 drug trial in the US is around $40m but can reach $100m for ultra large trials involving thousands of patients at hundreds of sites.

Puretech gave away c$13 billion when it farmed out KarXT now Cobenfy to Karuna which was subsequently bought for $14bilion by BMS.

Puretech obviously doesn't understand why it is a Public Company as it doesn't want to tap investment markets for capital to finance its corporate plans preferring to sell a large part of its prize assets to finance their development and cede potential significant gains to preserve its cash ( which rather ironically Lyne says a large part of which will be returned to shareholders once Celea and Gallop are funded)

A corporate omnishambles in other words as reflected by the awful share price performance and total lack of Investor interest as Stock Markets worldwide hit record highs.

Dispiriting indeed.